Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27703398 | 0.84 | ALDH1A1 (0.72) | ALDH1A1AGTR1KMT2AMEN1BCHE | |
| SCHEMBL24714971 | 0.83 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1MAPTPOLB | |
| SCHEMBL18954431 | 0.82 | ALDH1A1 (0.72) | ALDH1A1AGTR1KMT2AMEN1MAPT | |
| SCHEMBL18955121 | 0.81 | ALDH1A1 (0.53) | ALDH1A1AGTR1CES1CASP3 | |
| SCHEMBL18954565 | 0.81 | PARK7 (0.62) | ALDH1A1AGTR1CES1CASP3 | |
| SCHEMBL18954782 | 0.81 | ALDH1A1 (0.53) | ALDH1A1AGTR1KMT2ABCHECES1 | |
| SCHEMBL11959136 | 0.81 | ALDH1A1 (0.53) | ALDH1A1AGTR1CES1MAPTCASP3 | |
| SCHEMBL18954832 | 0.81 | APAF1 (0.48) | ALDH1A1AGTR1KMT2AMAPTHSD17B10 | |
| SCHEMBL18954721 | 0.81 | CUL4A (0.53) | ALDH1A1AGTR1KMT2AMEN1CES1 | |
| SCHEMBL14876312 | 0.81 | PARK7 (0.48) | ALDH1A1AGTR1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101415713-A | New spiro [imidazolidine-4, 3'-indole]-2,2',5 (1'H)-trione useful for the treatment of vanilloid receptor 1-related disorders | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | CN | claimed |
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| CN-101415713-A | New spiro [imidazolidine-4, 3'-indole]-2,2',5 (1'H)-trione useful for the treatment of vanilloid receptor 1-related disorders | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | CN | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007091948-A2 | NOVEL SPIRO [IMIDAZOLIDINE-4, 3´-INDOLE] 2, 2´,5´(1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-6774134-B2 | FOR THERAPY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | NESVADBA PETER (CH) | 2003-07-03 | — | — | US | disclosed |
| US-6503937-B1 | Coloring agents for high molecular weight materials such as polymers | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030121113-A1 | Oxobenzofuranylide-dihydroindolone | CYP1B1, CYP1A1, ECI1 | ALDH1A1 225/4885AGTR1 270/4885KMT2A 3786/4885 |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | ALDH1A1 550/4885AGTR1 37/4885KMT2A 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.